Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 217

Results For "disease"

2674 News Found

Experts point out key issues for vision loss at ASSOCHAM meet
Healthcare | February 24, 2022

Experts point out key issues for vision loss at ASSOCHAM meet

Cataract is the most common cause of blindness in India, and that diabetes is to be blamed for the massive number of damaged eyes


Bajaj Healthcare launches Magnesium L-Threonate in nutraceutical segment.
News | February 23, 2022

Bajaj Healthcare launches Magnesium L-Threonate in nutraceutical segment.

It is used to control, prevent and normalize the symptoms associated with Alzheimer's disease, attention disorder, bipolar disorder, Parkinson's disease among others


Omicron sublineage BA.2 a Variant of Concern: WHO
News | February 23, 2022

Omicron sublineage BA.2 a Variant of Concern: WHO

As part of its on-going work to track variants, WHO's Technical Advisory Group on SARS-CoV-2 Virus Evolution (TAG-VE) discussed the latest evidence on the Omicron variant of concern


MicroLumix’ GermPass kills Covid-19 virus in five seconds
Medical Device | February 23, 2022

MicroLumix’ GermPass kills Covid-19 virus in five seconds

New biotechnology product aims to be world's fastest automatic sanitary solution


Zydus receives USFDA approval for Dapagliflozin tablets
Drug Approval | February 23, 2022

Zydus receives USFDA approval for Dapagliflozin tablets

The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad


Complement Therapeutics raises €5 million seed financing
News | February 23, 2022

Complement Therapeutics raises €5 million seed financing

Appoints Dr Rafiq Hasan as CEO


Biorchestra announces US$45 million series C fundraising
News | February 23, 2022

Biorchestra announces US$45 million series C fundraising

he financing was significantly oversubscribed with high demand from both existing and new investors.


Vicore advances on new chemical entity from VP03 program
News | February 23, 2022

Vicore advances on new chemical entity from VP03 program

Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022


Bayer highlights pharma business plans on Media Day
News | February 23, 2022

Bayer highlights pharma business plans on Media Day

Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)


PrecisionLife appoints Colin Stubberfield as SVP Drug Discovery
People | February 22, 2022

PrecisionLife appoints Colin Stubberfield as SVP Drug Discovery

He will be responsible for developing the company's pipeline of partnered and in-house discovery programs,